Analytical methods
Sequencing of all coding exons and intron-exon boundaries of ABCC9 by Sanger sequencing, as part of a targeted gene panel for Mendelian syndromes, or by exome or whole genome sequencing. Sequencing of KCNJ8 by Sanger sequencing as a second line test, or concurrently with sequencing of ABCC9 as part of panel, exome or genome sequencing.
Analytical validation
Sanger sequencing is predicted to detect 499% of variants in the targeted regions of the two known genes. For other sequencing methods, sensitivity will depend on the characteristics of the test, including coverage of the coding regions and intron-exon boundaries, read depth and sequencing quality.
Estimated frequency of the disease
Incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report):
Unknown. There is no known variation in incidence or prevalence among ethnic groups. Comment: Testing is useful for confirming or making the diagnosis of Cantú syndrome in an affected individual. Testing of relatives allows assessment of reproductive risks -for example, in the parents of an affected child. Prenatal diagnosis is an option where one parent is affected and a pathogenic variant has been identified. Targeted non-invasive prenatal diagnosis (NIPD) is an emerging option for families in which the father is affected. NIPD may be possible where a previous affected child has a de novo variant, but the suitability of this will depend on the healthcare setting. 6 The clinical sensitivity of testing will depend at least in part on the extent to which alternative diagnoses have been excluded, on clinical grounds or by specific testing, prior to testing for variants in ABCC9 and KCNJ8.
Diagnostic setting

TEST CHARACTERISTICS
Clinical specificity (proportion of negative tests if the disease is not present)
The specificity of a clinical diagnosis can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
If the disease is not present, no pathogenic variants should be found in either ABCC9 or KCNJ8, and thus clinical specificity should be 100%.
Positive clinical predictive value (life-time risk of developing the disease if the test is positive)
Clinical features are usually present from childhood. Thus, positive clinical predictive value is mainly relevant in the context of prenatal diagnosis, in the setting of a known familial pathogenic variant. In that setting, positive clinical predictive value is likely to be close to 100%, with only the small risk of laboratory error or misinterpretation of a variant as pathogenic likely to lead to a genotype-positive fetus being clinically unaffected at birth.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100% if there is a proven pathogenic variant in the index case.
Index case in that family had not been tested: This depends on whether the clinical diagnosis in the proband is correct. If a confident clinical diagnosis has been made in the proband, negative clinical predictive value would be expected to be high (but difficult to quantify) in this scenario as well.
CLINICAL UTILITY
3.1.2 Describe the burden of alternative diagnostic methods to the patient The diagnosis of Cantú syndrome can be made on clinical grounds alone (hypertrichosis, distinctive facial features and the presence of other common features such as polyhydramnios and large birthweight). 7 However, diagnostic imaging can make a contribution to the diagnosis. This may include skeletal survey looking for the variable mild osteochondrodysplasia, as well as cardiomegaly. The burden of this to the patient relates mainly to radiation exposure. Echocardiography may also be useful. Patent ductus arteriosus is common. There may be cardiac enlargement, with high cardiac output probably due to reduced peripheral vascular resistance (not a cardiomyopathy, although the heart is often enlarged). 8 Blood pressure measurement (standing and prone) may be helpful. Pericardial effusion has also been observed, and some patients have pulmonary hypertension. Biochemistry is not diagnostic, but investigations such as urinary glycosaminoglycans and leucocyte enzymology for storage disorders may be helpful in excluding differential diagnoses (also low burden to the patient). Similarly, chromosome microarray could be considered to exclude 17q24.2-q24.3 copy number variants. Echocardiography, biochemistry and microarray testing all have a low burden for the patient.
How is the cost effectiveness of alternative diagnostic methods to be judged?
The investigations described above are relatively inexpensive individually. If there is strong clinical suspicion of Cantú syndrome, the combined expense of radiological investigations, biochemical testing and chromosome microarray are comparable to or exceed the cost of proceeding directly to sequencing of ABCC9/KCNJ8. However, echocardiography is indicated even in a patient with a confirmed diagnosis, because it is required for clinical management.
Will disease management be influenced by the result of a genetic test?
No □ Although most affected individuals have normal intellect, mild learning disabilities and particularly early motor delay have been observed. Knowledge of the diagnosis should prompt developmental evaluation in affected children and early intervention, if appropriate, to optimize developmental outcomes.
Management of hypertrichosis involves standard techniques for hair removal, including laser hair removal, although the severity of the hypertrichosis may limit the effectiveness of such measures.
For some affected individuals, the psychological impact of features of the condition, including hypertrichosis, the characteristic facial features and lymphedema is severe enough that psychological support may be of benefit.
A mild immune deficiency has been reported, 7 with recurrent infections out of proportion to mildly reduced immunoglobulin levels, which may respond to intravenous immunoglobulin.
Predictive Setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.9 'B' was marked) Yes. Children of affected individuals are at 1 in 2 risk of being affected. The risk to sibs where parents are unaffected is low, but recurrences have been reported in this setting, 9 presumably due to somatic or germline mosaicism. In either case, prenatal diagnosis using molecular testing is enabled by a positive genetic test result in the index patient. Targeted non-invasive prenatal diagnosis could also be used in the case of a de novo variant or when the father is affected.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) The main application of testing (other than the medical issues discussed in 3.1.4) is for reproductive purposes. In addition to the option of prenatal diagnosis (see 3.4.1) identification of a pathogenic variant in an adult makes it possible to consider preimplantation genetic diagnosis.
